Genmab's multiple myeloma drug wins fast-track status

04/4/2013 | RTT News

The FDA granted fast-track status to daratumumab, an experimental multiple myeloma drug being developed by Genmab and Janssen Biotech. The designation covers patients who already received at least three lines of treatments including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a PI and an IMiD, this article says.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC